We are monitoring the impact of COVID-19 on Europe Cancer Biomarkers Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 2148
Share on
Share on

European Cancer Biomarkers Market Research Report - Segmented By Disease, Services, Application, Type and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) – Size, Share, Trends, Growth, Forecast (2020 to 2025)

Pulished: February, 2020
ID: 2148
Pages: 145

European Cancer Biomarkers Market Size (2020 to 2025)

The size of the Cancer Biomarkers Market in Europe was worth USD 3.73 billion in 2020 and estimated to be growing at a CAGR of 11.2% to reach USD 6.34 billion by 2025.

The cancer diagnostics market is driven by increasing the commonness of different forms of cancer, growing cancer awareness, support of government initiatives and funding, and a rise in healthcare expenditure. The introduction of non-invasive screening methods and novel diagnostic biomarkers are likely to create new revenue streams and fuel the cancer diagnostics market over the next five years.

As a result of technological advances, Europe is experiencing significant growth. Growth is also primarily due to the increasing incidence of cancer and the rising senior population. The European cancer biomarkers market is also driven by rising rates of various forms of cancer, raising awareness of the disease, supporting government projects and funding, and increasing spending on health care. The implementation of non-invasive screening technologies and new diagnostic biomarkers is likely to generate new revenue streams in the next five years and boost the European cancer diagnostics market.

However, vague reimbursement scenario in certain countries and lack of specificity and sensitivity threaten to obstruct the growth of the cancer diagnostics market. The market is limited by high healthcare costs, reimbursement-related issues, and some regulatory policies that hamper market growth. However, the general population's lack of acceptance of the cancer biomarker, unfavorable salaries, and the lack of skilled workers could be some of the significant challenges facing the region's sector.

Because of the support created for biomarkers testing and the increasing number of people living with cancer in the area, the European market seems to have a tremendous opportunity to grow in personalized medicine. Besides, the different biomarker types of products and sub-segments prove to be quite profitable for market growth throughout the forecast period.

Europe Cancer Biomarkers Market segmented and sub-segmented into the following categories.

  • By Disease: Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Other Cancers
  • By Services: Sample Preparation, Assay Development, and Biomarkers Validation And Testing
  • By Application: Risk Assessment, Development Of Molecular Diagnostics, Disease Diagnosis, Drug Discovery And Development And Drug Formulation
  • By Type: Protein Biomarkers, Genetic Biomarkers, and Other Biomarkers.
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

Regionally, Europe accounts for the second-largest share in the global cancer biomarkers market. Because of technological developments, the European cancer biomarker market is experiencing significant growth.

The German cancer biomarkers market holds the largest market share in Europe in 2017, followed by the UK. Increasing the prevalence of cancer in this country and the presence of a high-quality healthcare system contributes to its largest share.

The increasing number of cancer patients and the government's support for research and innovation of biomarkers are helping the European market grow. Some of Europe's market-supporting organizations are the European Cancer Research Association, the German Translational Cancer Research Consortium, and the European Breast Cancer Specialist Society.

Some of the prominent companies leading the Europe Cancer Biomarkers Market profiled in this report are Abbott Laboratories, Agendia Bv, Biocurex Inc., Biomerieux S.A, Biomoda Inc., Astellas Pharma Us Inc., Correlogic Systems Inc., Beckman Coulter Inc., Becton Dickinson and Company, Clarient Inc., Diadexus Inc., Ambrilia Biopharma, Affymetrix Inc. and Aureon Laboratories Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Disease                        

                                5.1.1 Introduction           

                                5.1.2 Prostate Cancer    

                                5.1.3 Breast Cancer        

                                5.1.4 Lung Cancer            

                                5.1.5 Colorectal Cancer 

                                5.1.6 Cervical Cancer      

                                5.1.7 Other Cancers       

                                5.1.8  Y-o-Y Growth Analysis, By Disease               

                                5.1.9  Market Attractiveness Analysis, By Disease             

                                5.1.10  Market Share Analysis, By Disease            

                5.2 Services                       

                                5.2.1 Introduction           

                                5.2.2 Sample Preparation            

                                5.2.3 Assay development            

                                5.2.4 Biomarkers validation and testing 

                                5.2.5  Y-o-Y Growth Analysis, By Services              

                                5.2.6  Market Attractiveness Analysis, By Services            

                                5.2.7  Market Share Analysis, By Services             

                5.3 Application                 

                                5.3.1 Introduction           

                                5.3.2 Risk Assessment   

                                5.3.3 Development of molecular diagnostics       

                                5.3.4 Disease diagnosis 

                                5.3.5 Drug discovery      

                                5.3.6 Development and Drug formulation            

                                5.3.7  Y-o-Y Growth Analysis, By Application        

                                5.3.8  Market Attractiveness Analysis, By Application      

                                5.3.9  Market Share Analysis, By Application       

                5.4 Type                              

                                5.4.1 Introduction           

                                5.4.2 Protein Biomarkers             

                                5.4.3 Genetic biomarkers            

                                5.4.4 genetic biomarkers             

                                5.4.7  Y-o-Y Growth Analysis, By Type    

                                5.4.8  Market Attractiveness Analysis, By Type  

                                5.4.9  Market Share Analysis, By Type    

                5.5 Profiling Technologies                            

                                5.5.1 Omics technologies             

                                                5.5.1.1 Genomics

                                                5.5.1.2 Proteomics

                                                5.5.1.3 Metabolomics

                                                5.5.1.4 Transcriptomics

                                                5.5.1.5 Pharmacogenomics

                                5.5.2 Imaging technologies         

                                5.5.3 Immunoassays      

                                5.5.4 Cytogenetics          

                                5.5.5 Bioinformatics       

                                5.5.6 IVD multivariate index assays         

                                5.5.7  Y-o-Y Growth Analysis, By Profiling Technologies  

                                5.5.8  Market Attractiveness Analysis, By Profiling Technologies                

                                5.5.9  Market Share Analysis, By Profiling Technologies  

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Disease

                                                6.1.3.3 By Services

                                                6.1.3.4 By Application

                                                6.1.3.5 By Type

                                                6.1.3.6 Profiling Technologies

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Disease

                                                6.1.4.3 By Services

                                                6.1.4.4 By Application

                                                6.1.4.5 By Type

                                                6.1.4.6 Profiling Technologies

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Disease

                                                6.1.5.3 By Services

                                                6.1.5.4 By Application

                                                6.1.5.5 By Type

                                                6.1.5.6 Profiling Technologies

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Abbott Laboratories                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Agendia Bv                 

                8.3 Biocurex Inc                               

                8.4 Biomerieux S.A.                        

                8.5 Biomoda Inc                               

                8.6 Astellas Pharma Us Inc                          

                8.7 Correlogic Systems Inc                           

                8.8 Beckman Coulter Inc                              

                8.9 Becton                          

                8.10 Dickinson And Company                     

                8.11 Clarient Inc                               

                8.12 Diadexus Inc                            

                8.13 Ambrilia Biopharma                              

                8.14 Affymetrix Inc                         

                8.15 Aureon Laboratories Inc.                    

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Cancer Biomarkers Market, By Disease, From 2020 to 2025 (USD Million)
  2. Europe Prostate Cancer Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe Breast Cancer Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe Lung Cancer Market, By Region, From 2020 to 2025 (USD Million)
  5. Europe Colorectal Cancer Market, By Region, From 2020 to 2025 (USD Million)
  6. Europe Cervical Cancer  Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe Other Cancers Market, By Region, From 2020 to 2025 (USD Million)
  8. Europe Cancer Biomarkers Market, By Services, From 2020 to 2025 (USD Million)
  9. Europe Sample Preparation Market, By Region, From 2020 to 2025 (USD Million)
  10. Europe Assay development  Market, By Region, From 2020 to 2025 (USD Million)
  11. Europe Biomarkers validation and testing Market, By Region, From 2020 to 2025 (USD Million)
  12. Europe Cancer Biomarkers Market, By Application, From 2020 to 2025 (USD Million)
  13. Europe Risk Assessment Market, By Region, From 2020 to 2025 (USD Million)
  14. Europe Development of molecular diagnostics Market, By Region, From 2020 to 2025 (USD Million)
  15. Europe Disease diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  16. Europe Drug Discovery  Market, By Region, From 2020 to 2025 (USD Million)
  17. Europe Development and Drug formulation Market, By Region, From 2020 to 2025 (USD Million)
  18. Europe Cancer Biomarkers Market, By Type, From 2020 to 2025 (USD Million)
  19. Europe Protein Biomarkers Market, By Region, From 2020 to 2025 (USD Million)
  20. Europe Genetic biomarkers  Market, By Region, From 2020 to 2025 (USD Million)
  21. Europe Other biomarkers Market, By Region, From 2020 to 2025 (USD Million)
  22. Europe Cancer Biomarkers Market, By Profiling Technologies, From 2020 to 2025 (USD Million)
  23. Europe Omics technologies  Market, By Region, From 2020 to 2025 (USD Million)
  24. Europe Imaging technologies Market, By Region, From 2020 to 2025 (USD Million)
  25. Europe Immunoassays Market, By Region, From 2020 to 2025 (USD Million)
  26. Europe Cytogenetics Market, By Region, From 2020 to 2025 (USD Million)
  27. Europe Bioinformatics Market, By Region, From 2020 to 2025 (USD Million)
  28. Europe IVD multivariate index assays Market, By Region, From 2020 to 2025 (USD Million)
  29. U.K. Cancer Biomarkers Market, By Disease, From 2020 to 2025 (USD Million)
  30. U.K. Cancer Biomarkers Market, By Services, From 2020 to 2025 (USD Million)
  31. U.K. Cancer Biomarkers Market, By Application, From 2020 to 2025 (USD Million)
  32. U.K. Cancer Biomarkers Market, By Type, From 2020 to 2025 (USD Million)
  33. U.K. Cancer Biomarkers Market, By Profiling Technologies, From 2020 to 2025 (USD Million)
  34. Germany Cancer Biomarkers Market, By Disease, From 2020 to 2025 (USD Million)
  35. Germany Cancer Biomarkers Market, By Services, From 2020 to 2025 (USD Million)
  36. Germany Cancer Biomarkers Market, By Application, From 2020 to 2025 (USD Million)
  37. Germany Cancer Biomarkers Market, By Type, From 2020 to 2025 (USD Million)
  38. Germany Cancer Biomarkers Market, By Profiling Technologies, From 2020 to 2025 (USD Million)
  39. France Cancer Biomarkers Market, By Disease, From 2020 to 2025 (USD Million)
  40. France Cancer Biomarkers Market, By Services, From 2020 to 2025 (USD Million)
  41. France Cancer Biomarkers Market, By Application, From 2020 to 2025 (USD Million)
  42. France Cancer Biomarkers Market, By Type, From 2020 to 2025 (USD Million)
  43. France Cancer Biomarkers Market, By Profiling Technologies, From 2020 to 2025 (USD Million)
  44. Italy Cancer Biomarkers Market, By Disease, From 2020 to 2025 (USD Million)
  45. Italy Cancer Biomarkers Market, By Services, From 2020 to 2025 (USD Million)
  46. Italy Cancer Biomarkers Market, By Application, From 2020 to 2025 (USD Million)
  47. Italy Cancer Biomarkers Market, By Type, From 2020 to 2025 (USD Million)
  48. Italy Cancer Biomarkers Market, By Profiling Technologies, From 2020 to 2025 (USD Million)
  49. Spain Cancer Biomarkers Market, By Disease, From 2020 to 2025 (USD Million)
  50. Spain Cancer Biomarkers Market, By Services, From 2020 to 2025 (USD Million)
  51. Spain Cancer Biomarkers Market, By Application, From 2020 to 2025 (USD Million)
  52. Spain Cancer Biomarkers Market, By Type, From 2020 to 2025 (USD Million)
  53. Spain Cancer Biomarkers Market, By Profiling Technologies, From 2020 to 2025 (USD Million)
  54. Europe Cancer Biomarkers Market, By Omics technologies, From 2020 to 2025 (USD Million)
  55. Europe Genomics Market, By Region, From 2020 to 2025 (USD Million)
  56. Europe Proteomics Market, By Region, From 2020 to 2025 (USD Million)
  57. Europe Metabolomics Market, By Region, From 2020 to 2025 (USD Million)
  58. Europe Transcriptomics Market, By Region, From 2020 to 2025 (USD Million)
  59. Europe Pharmacogenomics Market, By Region, From 2020 to 2025 (USD Million)
  60. U.K. Cancer Biomarkers Market, By Omics technologies, From 2020 to 2025 (USD Million)
  61. Germany Cancer Biomarkers Market, By Omics technologies, From 2020 to 2025 (USD Million)
  62. France Cancer Biomarkers Market, By Omics technologies, From 2020 to 2025 (USD Million)
  63. Italy Cancer Biomarkers Market, By Omics technologies, From 2020 to 2025 (USD Million)
  64. Spain Cancer Biomarkers Market, By Omics technologies, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample